Avid Bioservices Inc (CDMO)

[freethemice]

Sorry, this is a reply to
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=88410900
As exwannabe noted, the patients had not progressed after their initial radiochemotherapy treatment.
This is totally different than the bavi second-line trial, or any second-line trial, that enrolls
patients who have progressed after their initial treatment. The patients enrolled also had
locally advanced stage III disease, and not metastatic disease. The subgroup is interesting in
that it was prespecified, and the MOS was statistically significant (p=0.0160). The number of
patients in that subgroup was quite large (n=806).
http://www.4-traders.com/ONCOTHYREON-INC-1411129/news/Oncothyreon-Inc-Oncothyreon-Announces-Data-for-L-BLP25-and-PX-866-to-be-Presented-at-American-Soci-16866805/